Evoke Pharma Shows Strong Financial Results for Q2 2025
Evoke Pharma, Inc. (NASDAQ: EVOK), a pharmaceutical company specializing in treatments for gastrointestinal disorders, has recently released its financial results for the second quarter. With a focus on its product GIMOTI, the company is celebrating significant achievements in sales growth and market adoption.
Quarter Highlights and Developments
During this quarter, Evoke Pharma demonstrated impressive growth with net product sales reaching approximately $3.8 million, marking a 47% increase compared to the same period last year. This growth is attributed to enhanced pharmacy access and increasing physician prescriptions.
Key Metrics of Growth
- The number of new prescribers rose 20% year-over-year, showcasing a positive trend within the gastroenterology sector.
- Refill rates remained stable at around 70%, indicating consistent therapeutic benefits of GIMOTI for patients.
- Real-world safety data presented at a major digestive disease conference highlighted GIMOTI’s efficacy compared to traditional metoclopramide usage.
Financial Overview for Q2 2025
In reviewing the financials for the quarter, total operating expenses increased to approximately $5.3 million compared to $3.8 million in Q2 2024. Major contributors included increased profit-sharing costs due to the uptick in net product sales and heightened professional fees.
Cash Position and Future Outlook
As of June 30, 2025, Evoke’s cash and cash equivalents totaled approximately $12.1 million, projected to support its operational needs until the third quarter of 2026 based on current sales trends.
Guidance for 2025
Evoke Pharma is reaffirming its guidance for full-year 2025 net product sales, predicting approximately $16 million—an expected increase of 60% over last year. This outlook considers the current trends in prescription growth, refill rates, and overall market demand for GIMOTI.
About Evoke Pharma, Inc.
Founded to develop innovative therapies for gastrointestinal disorders, Evoke has successfully brought GIMOTI to market. This nasal spray formulation of metoclopramide offers a vital alternative to patients suffering from diabetic gastroparesis, a condition that affects many worldwide.
What is Diabetic Gastroparesis?
Diabetic gastroparesis is a serious disorder where the stomach takes too long to empty its contents, leading to various complications, including poor nutrient absorption. Prior to the approval of GIMOTI, metoclopramide was available only in oral and injectable forms.
Investor Contact Information
For further inquiries, please contact:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
Email: dboateng@dkbpartners.net
Frequently Asked Questions
What trends contributed to Evoke Pharma's growth this quarter?
The growth has been fueled by a 47% annual increase in net product sales and a growing number of new prescribers, reflecting strong demand for GIMOTI.
How is Evoke Pharma's financial outlook for 2025?
For 2025, Evoke Pharma anticipates net product sales of about $16 million, projecting a significant increase compared to the previous year.
What is GIMOTI and its importance?
GIMOTI is a nasal spray designed for patients with diabetic gastroparesis, offering a crucial treatment option that enhances medication absorption compared to traditional forms.
How does Evoke Pharma plan to sustain its growth?
The company aims to continue expanding pharmacy access and increasing physician adoption to bolster its market presence and sales.
What are the risks associated with GIMOTI?
While GIMOTI is effective, potential risks include adverse side effects commonly associated with metoclopramide, such as tardive dyskinesia.
